Get in touch
Connect with THCA Therapeutics.
We welcome focused conversations with investors, scientists, development partners and organizations interested in the rigorous pharmaceutical evaluation of purified THCA.
THCA Therapeutics is a Munich-based biotechnology business focused on the pharmaceutical evaluation of purified THCA. Please select the inquiry route that best matches your interest so the conversation can begin with the right context.
Choose the most relevant conversation.
Each contact route opens a prepared email with the appropriate subject line. Add a short introduction, your organization and the reason for your inquiry.
Investment & strategic financing
Discussions regarding Seed financing, syndication, strategic investment and long-term biotechnology value creation.
- Request non-confidential investor materials
- Discuss the development and financing strategy
- Explore strategic-investor alignment
Scientific & academic collaboration
Engagement with researchers and clinicians in rheumatology, immunology, cannabinoid science, pharmacology and translational medicine.
- Scientific-advisory discussions
- Academic or translational collaboration
- Evidence review and study-concept exchange
CRO, CDMO & laboratory partners
Feasibility and capability discussions with qualified analytical, formulation, manufacturing, nonclinical, clinical and regulatory service providers.
- Analytical and formulation capabilities
- Phase-appropriate CMC and manufacturing
- Nonclinical, clinical or regulatory execution
General, media & other inquiries
Contact THCA Therapeutics regarding the project, public information, speaking opportunities, media requests or other relevant matters.
- General project questions
- Media and communications
- Relevant professional introductions
One central contact point.
Use the central business email for all initial inquiries. Messages can then be directed to the appropriate scientific, strategic, development or legal contact as the organization and partner network develop.
EMAIL THCA THERAPEUTICS info@thcatherapeutics.comA useful first message includes:
-
Who you are
Your name, role, organization and location.
-
Why you are contacting us
The specific investment, scientific or development topic.
-
What you are proposing
The discussion, capability, collaboration or introduction you have in mind.
-
Relevant supporting context
A company profile, publication, capability statement or professional link.
Request the current investor overview.
Qualified investors and strategic financing partners may request the current non-confidential presentation and arrange an introductory discussion with the founder.
Materials are provided for discussion purposes and do not constitute an offer of securities.
Where relevant expertise can add value.
The business is building the multidisciplinary network required to move from a documented thesis toward candidate-level evidence and regulatory readiness.
Rheumatology & immunology
Lead-indication strategy, translational biology, biomarker selection and future clinical-development input.
Cannabinoid pharmacology
THCA-specific pharmacology, mechanism interpretation, exposure and preclinical-study design.
Analytical & formulation science
Material characterization, analytical methods, product feasibility, stability and phase-appropriate quality strategy.
Nonclinical development
Pharmacology, safety, bioanalysis and evidence packages suitable for regulator-informed progression.
Regulatory & clinical strategy
EU development planning, scientific advice, CMC integration and first-in-human readiness.
Financing & governance
Seed financing, Corporate governance and organizational development, governance and strategic network development.
Share enough to begin—without sending confidential information.
Initial contact should remain non-confidential. A suitable confidentiality arrangement can be considered before detailed proprietary information is exchanged.
Initial outreach
Provide a concise, non-confidential introduction and the purpose of the proposed discussion.
Mutual relevance
THCA Therapeutics will assess strategic fit, timing and the appropriate participants for a first conversation.
Confidential discussion
Sensitive scientific, commercial or technical details should be shared only after an appropriate written arrangement is in place.
By contacting THCA Therapeutics, you provide information for the purpose of responding to your inquiry. Please review the website’s privacy information before submitting personal data.
The right collaboration can accelerate the path from question to proof.
THCA Therapeutics is a Munich-based biotechnology business operated by Farbod Parvin as a sole proprietor. THCA PURE™ Oral and THCA PURE™ Inhale are investigational development concepts and are not approved for medical or commercial use. No product-specific human efficacy, safety, stability, bioavailability, patent protection or freedom-to-operate conclusion is claimed.
